Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
236 hedge funds and large institutions have $3B invested in Array Biopharma Inc in 2018 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 74 increasing their positions, 74 reducing their positions, and 27 closing their positions.
150% more call options, than puts
Call options by funds: $31.1M | Put options by funds: $12.4M
111% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 27
13% more funds holding
Funds holding: 208 → 236 (+28)
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
0% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 74
4% less capital invested
Capital invested by funds: $3.11B → $3B (-$111M)
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$99.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$69.7M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$28.1M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$23.1M |
| 5 |
Goldman Sachs
New York
|
+$21.1M |
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$73.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$25.4M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$23.5M |
| 4 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$11.7M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$11.2M |
ARRY Hedge Fund Activity: Q4 2018 in Review
236 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q4 2018, worth a combined $3B — down 3.6% from $3.11B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new ARRY positions and 27 closed out — a net gain of 30 holders — while 74 added to existing stakes and 74 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $99.2M. The largest seller was OrbiMed, exiting entirely with an estimated $73.1M sold.
- 236 institutional investors held Array Biopharma Inc (ARRY) as of Q4 2018, up from 208 in Q3 2018.
- Funds reported $3B of Array Biopharma Inc stock for Q4 2018, down 3.6% quarter-over-quarter.
- 57 funds opened new Array Biopharma Inc positions in Q4 2018 and 27 closed out, a net change of +30 holders.
- The largest Array Biopharma Inc buyer in Q4 2018 was Point72 Asset Management, an estimated $99.2M added.
- The largest Array Biopharma Inc seller in Q4 2018 was OrbiMed, an estimated $73.1M sold.
Based on aggregated 13F filings for Q4 2018.